2015 PRESCRIPTION DRUG PRICES JUMP ANOTHER 3.8% IN Q1, ACCORDING TO TRUVERIS NATIONAL DRUG INDEX

Branded Medications Jump 5.7%; Specialty Drugs Rise 2.5%; Generics Up 1.4%

NEW YORK, April 28, 2015 – Truveris, a leading platform for prescription drug pricing and benefits analysis, continues to spotlight prescription drug cost increases with 2015 data from the Truveris National Drug Index (NDI), which shows branded, specialty and generic drugs rose a combined 3.8% in the first quarter.

Analyzed by category, branded drug prices jumped 5.7%, specialty drugs rose 2.5% and generic drugs increased 1.4% between January and March 2015. The increases follow those reported for calendar year 2014, in which branded, specialty and generic medications increased 14.8%, 9.7% and 4.9%, respectively, and 10.9% combined overall.

The index also points to infertility (12.2%), menopause (8.8%) and hormone deficiency (8.5%) as conditions that saw the highest drug price increases, taking into account composite calculations of brand, specialty and generic medications. Generic drugs for menopause notably spiked 11.1%, increasing at a higher rate than the composite calculation.

"Prscription drug prices continue to rise at a rate that makes it increasingly difficult for businesses to keep the costs of employee benefits in check," said Bryan Birch, Chairman, President and CEO of Truveris. "This necessitates that benefit plan managers act now to reevaluate benefit plan designs for 2016, or contemplate stop-loss insurance to cover this mo

The Truveris National Drug Index (NDI) is the only prescription drug price index in the U.S. measuring the average price of prescription drugs, driven by the most commonly utilized prescriptions. Calculated monthly, it provides a holistic, accurate measurement of the prices paid by private insurers, self-insured organizations, government, unions and uninsured patients.

The current index shows:

Truveris NDI Composite

  • Between January and March 2015, the NDI composite index increased 22.52 points or 3.8%.
  • For the month of March, the Truveris NDI rose 1.78 points or 0.29%.

Truveris NDI Brand

  • Between January and March 2015, the brand index increased 17.39 points or 5.7%.
  • For the month of March, the Truveris NDI Brand rose 1.00 points or 0.31%.

Truveris NDI Generic

  • Between January and March 2015, the generic index increased 2.1 points or 1.4%.
  • For the month of March, the Truveris NDI Generic rose 0.21 points or 0.14%.

Truveris NDI Specialty

  • Between January and March 2015, the specialty index increased 3.49 points or 2.5%.
  • For the month of March, the Truveris NDI Specialty rose 0.58 points or 0.41%.

About Truveris

Truveris is the leading prescription drug analytics company, on a mission to democratize data and access through technology. Our proprietary Software-as-a-Service platforms drive transparency and lower costs across the pharmacy benefit ecosystem: solutions including RxChoice®, TruBid® and RxDashSM enable clients to select a pharmacy benefit vendor and anticipate financial trends and projected annual spend with unprecedented accuracy and efficiency. Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. For more information, check out rxchoice.com, or contact us at [email protected]

# # #

© 2015 Truveris, Inc. All rights reserved.

All trademarks indicated above are owned by Truveris.

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?